Kornimate/medical-research-clean huggingface dataset:
relationship between microbiota and prognosis of hepatocellular carcinoma(hcc) after systemic treatments

Conditions: Liver Cancer; Microbiota; Adverse Event; Prognosis; Efficacy

Summary: by tracking the short-term and long-term results of hcc patients treated with systemic therapies,the difference of microbiota between responded patients and non-responded patients was analyzed, and the correlation between gut and oral microbiota and short-term and long-term results was explored, so as to improve people's awareness of microbiota and pay attention to its prevention and treatment.

the investigators consecutively admit patients the questionnaire and collect the fecal. and by tracking the short-term and long-term outcomes of hcc patients treated with systemic therapies,the difference of gut microbiota between responded patients and non-responded patients is analyzed, and the correlation between gut and oral microbiota and short-term and long-term results is explored.adverse events (ae) are recorded using the national cancer institute's common terminology criteria for adverse events (version 4.0).tumor response is mainly evaluated by experienced hepatologists using radiological method within 4-12 weeks after treatments according to the recist 1.1 and modified response evaluation criteria in solid tumors (mrecist).overall survival (os) and progression-free survival (pfs) are recorded.

Eligibility criteria:
inclusion criteria: * clinically or pathologically diagnosed hcc * didn't receive prior anti-tumor treatments * didn't receive prior antibiotics * eastern cooperative oncology group performance status (ecog-ps) 0-1 * child-pugh score of ≤7 * complete clinical and follow-up information. exclusion criteria: * combined with other malignancies * receive surgical treatment * lost follow-up * child-pugh score of\>7 * uncompleted clinical and follow-up information * overall survival less than 1 month * receive prior antibiotics

Keywords: hcc microbiota adverse event prognosis efficacy
comparison of tibial plateau fractures outcomes treated with non-locking and locking plate

Conditions: Tibial Fracture

Summary: this study will perform to compare the results and functional outcomes of tibial plateau fractures treated with non-locking and locking plate fixation.


Eligibility criteria:
inclusion criteria: * unilateral closed tibia plateau fracture exclusion criteria: * patients who have been treated with casting or screw * history of diabetes mellitus * evidences of pathological fractures
peer education on core health outcomes specific for burn patients

Conditions: Burns

Summary: evaluate the effectiveness of peer education on core health outcomes specific for burn patients

a randomized controlled study will done in the plastic \& reconstructive burn center at mansoura university hospitals. the first phase includes the systematic collection of data to assess patient's health status and determine any actual or potential health problems after necessary permission taken. the researcher will design the proposed peer education and educational media based on the findings of the assessment. after peers training, implementing peer education for the study group. the final step of data collection is evaluating the patient's response to the proposed program and the extent to which the outcomes have been achieved.

Eligibility criteria:
inclusion criteria for patients: recently admitted patients * hemodynamically stable and free from chronic disease * conscious, able to communicate inclusion criteria for peer: * old burns injury patients at least have a diploma degree exclusion criteria: -

Keywords: burn specific health scale burn patients peer education
brief smoking intervention for women undergoing breast cancer surgery

Conditions: Breast Cancer; Smoking

Summary: the primary purpose of this study is to examine the effect of a brief preoperative smoking intervention on postoperative complications in women undergoing breast cancer surgery. secondary purposes are to examine long-term smoking cessation rates and experienced stress and nicotine withdrawal symptoms during the smoking cessation period.

smokers are at greater risk of developing postoperative complications. the connection between smoking and cardiovascular and pulmonary disease is furthermore well documented. smoking cessation 6 weeks before orthopaedic surgery significantly reduces the risk of developing postoperative complications. however, smoking cessation for an even shorter period may theoretically have similar effects on postoperative complications. intensive smoking intervention programmes increase long-term smoking cessation rates significantly. little evidence is available on the efficacy of brief smoking intervention programmes for newly diagnosed cancer patients. this study therefore aims to examine the effect of a brief smoking intervention on postoperative complications and long-term smoking cessation rates in women undergoing breast cancer surgery. the study is a randomised clinical trial in which study participants are randomised by block randomisation to either standard care (control group) or a brief preoperative smoking intervention (intervention group). patients in the intervention group are counselled to comply with an intended perioperative smoking cessation period of 13 days. the intervention and control groups will be compared up to 12 months postoperatively in regard to frequency of postoperative complications and smoking cessation rates. additionally, experienced stress and nicotine withdrawal symptoms during the perioperative smoking cessation period will be compared between the groups.

Eligibility criteria:
inclusion criteria: * woman * scheduled for elective breast cancer surgery * daily smoker * age 18 years and above * able to read and write danish * informed consent. exclusion criteria: * alcohol intake \>35 units per week * diagnosed psychiatric disease (including substance abuse and dementia) * asa iv and v * preoperative neo-adjuvant chemotherapy * ulcerating cancer * pregnancy and breast-feeding.

Keywords: smoking cessation stress nicotine dependence complication, postoperative
myocardial infarction registry

Conditions: Acute Coronary Syndrome

Summary: the single-center mir-registry was created to assess real-world prevalence, demographic characteristics and management of patients with acute coronary syndrome presenting in the emergency department (ed) of university of heidelberg.

to conduct a comprehensive characterization of patients with symptoms of acute coronary syndrome or elevated troponin levels. records include clinical routine parameters, there will be an expansion involving the collection of blood samples for the analysis of novel laboratory-based and omics-based biomarkers. the acs registry is monothetically managed by the department of internal medicine iii at heidelberg university hospital and is intended to serve as a basis for further clinical diagnostic and outcome studies. the blood samples will serve as the foundation for a comprehensive analysis of established and novel laboratory-based markers, as well as omics-based biomarkers (mirna, metabolomics, and proteomics). follow-up was performed via review of medical reports, phone calls and postal queries. the outcome parameters comprised rates for all-cause mortality, non-hemorrhagic stroke, myocardial infarction, and hospitalization for any cause.

Eligibility criteria:
inclusion criteria: the study will include consecutive patients who present to the cardiology emergency department at heidelberg university hospital with symptoms of acute coronary syndrome or a troponin increase (hs-tnt \>14 ng/l). additional inclusion criteria are a minimum age of 18 years and providing informed consent through written consent to participate in the study. the following medical conditions are intended to be distinguished from one another: * acute myocardial infarction * unstable angina pectoris * myocarditis * heart failure * cardiomyopathies * pulmonary embolism * renal insufficiency * supraventricular and ventricular tachycardias * hypertensive crisis * non-cardiac chest pain exclusion criteria: exclusion criteria are defined according to gcp (good clinical practice), i.e., mental illnesses/dementia (lack of capacity to provide informed consent), pregnancy/breastfeeding, as well as acute conditions requiring immediate treatment (e.g., cardiogenic shock).
efficacy and safety of amodiaquine and amodiaquine-artesunate

Conditions: Malaria

Summary: the purpose of this study is to compare the efficacy and safety of two antimalarial drug regimes, namely amodiaquine versus amodiaquine-artesunate, in the treatment of children with uncomplicated malaria. also, genetic host factors which might influence efficacy and/or safety will be examined.

malaria remains a major cause of morbidity and mortality among children in sub-saharan africa. current malaria control largely consists of rapid treatment of patients. amodiaquine-artesunate and other combinatory treatment regimes including amodiaquine are now being introduced as first-line antimalarial drugs in several african countries. however, data on the efficacy and safety of amodiaquine and amodiaquine-artesunate are scarce. in addition, there is evidence that common genetic host factors, e.g. sickle cell trait, may influence efficacy and safety of these drugs. to examine efficacy and safety of the named drugs as well as a potential influence of genetic host factors on these outcomes a randomized, double blind trial among 400 children with uncomplicated malaria is performed in northern ghana.

Eligibility criteria:
inclusion criteria: * male and female outpatients aged 6 to 59 months * body weight \>5 kg * uncomplicated plasmodium falciparum malaria * mono-infection with p. falciparum with an asexual parasite density between 2,000 to 200,000 parasites/μl * axillary temperature ≥37.5°c * ability to tolerate oral therapy * informed consent by the legal representative of the subject * residence in study area exclusion criteria: * previous participation in this clinical trial * haemoglobin \<5 mg/dl * mixed plasmodial infection * danger signs (unable to drink; repeated vomiting; recent history of convulsions;lethargic or unconscious state; unable to stand up or to sit) and signs of severe malaria as defined by who. * any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known hiv infection) * concomitant disease masking assessment of response * history of allergy or intolerance against study medications

Keywords: malaria, amodiaquine, artesunate, safety, efficacy
correlation between changes in end-tidal carbon dioxide and stroke volume variation detected by electrical cardiometry as a predictor of fluid volume responsiveness in hemodynamically unstable patients in the intensive care

Conditions: End Tidal Carbon Dioxide; Cardiometry; Fluid Responsiveness; Shock

Summary: this study will be conducted to assess the role of end-tidal carbon dioxide (petco2) monitoring to predict the fluid volume responsiveness in correlation with stroke volume variation detected by electrical cardiometry in patients with hemodynamic instability.


Eligibility criteria:
inclusion criteria: * patients who will be 18 years or older. * patients on mechanical ventilation in the intensive care. * patients developing hypotension (mabp) \<65 mmhg. exclusion criteria: * patients with organ/s failure at presentation. * patients with deep venous thrombosis. * patients with limb and pelvic fractures. * pregnant patients
breathing with a facemask exercise performance

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this study will determine the dyspnea response in chronic lung disease volunteers during treadmill walking with and without added inspiratory resistance. this study will also determine the level of dyspnea and exercise sense of effort in individuals walking on a treadmill when elevations occur. comparisons will be made of a participant's exercise response with and without increased inspiratory resistance. in this study, exercise performance will be analyzed based on physiological and perceptual measures. the participant will undergo two sessions: one session will be a standard exercise walking test without an inspiratory resistance; the other session will be the same standard exercise walking test while breathing with an inspiratory resistance equal to a n95 facemask (r=10-15 cmh2o/l/sec). performance will be determined by physiological measures. perception will be determined by scores based on numerical scales and automatically with the forehead vitality remote monitoring sensor.


Eligibility criteria:
inclusion criteria: * former pulmonary rehabilitation patients that are now participating in maintenance exercise classes * males and females with an age range of 18 years or older * subjects must be able to walk on treadmill for multiple sessions exclusion criteria: * the subjects in each experiment will be recruited for a distribution of gender, ethnicity and age
it is possible to maintain the performance of screening colonoscopies under meopa during the covid 19 epidemic period when access to the operating room is limited

Conditions: Colorectal Cancer

Summary: feedback: during the covid-19 epidemic, access to operating theaters was restricted so that anesthetists and nurse anesthetists could reinforce the resuscitation workforce. the meopa was used as an alternative to sedation, allowing colonoscopies to be carried out, colon polyps and colorectal cancers to be detected.

colonoscopy is a major procedure for screening for cancers and diagnosing colorectal lesions. in france, general anesthesia remains the most widely used sedation method for colonoscopy. faced with several constraints such as difficulty of access to the operating room, length of hospitalization and contraindications to general anesthesia, several sedation methods have been adopted. the best known is sedation by meopa (equimolar mixture of oxygen protoxide of nitrogen) marketed under the name of kalinox. it is offered as a second-line treatment after general anesthesia. since march 2020, the covid-19 health crisis has forced us to change our care. faced with restricted access to the operating room (anesthetists and nurse anesthetists requisitioned to participate in the care of patients in intensive care), colonoscopy under meopa was offered to patients who could have benefited from general anesthesia before the crisis. this monocentric retrospective descriptive study at the chsf (centre hospitalier sud francilien) will make it possible to assess the quality of colonoscopies performed under meopa in the first line. this is a feedback, the meopa having allowed us to continue and maintain the performance of screening colonoscopies during the covid 19 epidemic.

Eligibility criteria:
inclusion criteria: * adult patients who had a colonoscopy under meopa between january 2019 and may 2021 at the chsf. exclusion criteria: * colonoscopy under general anesthesia * refusal of data collection.

Keywords: type of anesthesia colonoscopy and polypectomy colorectal cancer colonoscopy quality indicator covid 19
a phase ii study of dexamethasone, azacitidine, pegaspargase and tislelizumab plus radiotherapy for patients with stage i/ii extranodal nk/t-cell lymphoma

Conditions: NK/T Cell Lymphoma

Summary: the goal of this clinical trial is to learn if the regimen of dexamethasone, azacitidine, pegaspargase and tislelizumab (dapt regimen) combined with radiotherapy works to treat stage i or ii nk/t cell lymphoma in adults. it will also learn about the safety of the dapt regimen. the main questions it aims to answer are: what are the efficacy of the dapt regimen plus radiotherapy in participants with extranodal nk/t-cell lymphoma? what medical problems do participants have when taking the dapt regimen? participants will: receive the dapt regimen every 21 days for 6 cycles and radiotherapy visit the clinic according to clinical trial requirement for checkups and tests receive blood tests and radiological imaging tests according to the clinical trial requirement


Eligibility criteria:
inclusion criteria: 1. pathologically confirmed diagnosis of extranodal nk/t-cell lymphoma 2. age ≥18 years 3. ann arbor stage i or ii 4. presence of at least 1 measurable lesion according to the 2014 lugano revised criteria for response assessment 5. ecog-ps 0\~2 6. peripheral blood absolute neutrophil count ≥1.5×10e9/l, platelet count ≥75×10e9/l and hemoglobin ≥90g/l 7. expected survival of at least 3 months 8. capable of understanding the content of this study, agreeing to participate in this study and signing the informed consent. exclusion criteria: 1. unconfirmed pathological diagnosis of nk/t-cell lymphoma 2. pregnant or lactating women, or patients of childbearing age unwilling to take contraceptive measures during the study period. 3. patients with clinically significant prolonged qtc interval (\>470ms in males, \>480ms in females), ventricular tachycardia, atrial fibrillation, second or third degree atrioventricular block, acute myocardial infarction, congestive heart failure, severe or symptomatic coronary artery disease requiring medical treatment. 4. patients with large amount of pericardial effusions shown by echocardiogram. 5. patients who received supportive care for anemia, neutropenia or thrombocytopenia within 7 days prior to start of study treatment. 6. patients with severe active bleeding. 7. patients with pulmonary embolism, intracranial hemorrhage or acute cerebral infarction. 8. patients with active infectious disease. 9. patients who are mentally disabled or unable to understand or sign the informed consent form. 10. patients with other conditions judged as ineligible for this study by the investigators.

Keywords: nk/t cell lymphoma
smartmanage stress management for hiv+ cancer survivors

Conditions: Cancer; Hiv; Stress

Summary: the purpose of this study is to design and refine a web-based platform developed for managing symptom burden in men who have sex who are hiv+ cancer survivors.


Eligibility criteria:
inclusion criteria: 1. age: 18 years or older 2. fluent in english 3. have evidence of at least one form of non-metastatic solid tumor cancer or blood cancer 4. be at least 30 days post active primary cancer treatment 5. self identify as a sexual minority cisgender man 6. self-report having been diagnosed with hiv 7. have reliable access to a computer/device with internet accessibility exclusion criteria: 1. have had one of the following exclusionary cancer types: non-melanoma skin cancer, brain cancer, eye cancer, history of some form of pediatric cancer (if that is participant's only cancer diagnosis) 2. history of advanced (metastatic) cancer of any type 3. inpatient treatment for severe mental illness in the past 12 months and/or suicidality of moderate or greater risk 4. appears actively intoxicated or otherwise unable to provide full informed consent 5. have any other medical condition resulting in predicted live expectancy of less than 12 months

Keywords: symptom burden cognitive behavioral stress management intervention development
riboflavin mediated corneal crosslinking for stabilizing progression of keratoconus

Conditions: Keratoconus

Summary: background: corneal cross linking is a procedure that induces collagen cross linking of the corneal stroma due to release of reactive oxygen radicals upon activation of topically applied riboflavine a by uva exposure. this procedure might be capable of reducing keratocouns progression. purpose: although there are no randomised controlled trials on the effectiveness of corneal cross linking for the treatment of keratoconus it gains more and more importance in the general clinical setting. therefore, the investigators started such randomised, placebo controlled, double blinded, multicenter trial to find out if this treatment is as effective as it promises to be. methods: randomised, placebo controlled, double blinded, multicenter trial.


Eligibility criteria:
inclusion criteria: * only early keratoconus (contact lens fitting) * progression of ametropia. * corneal thickness \> 450µm exclusion criteria: * further ophthalmic diseases * history of ocular surgery * pregnancy, brest feeding * allergy against riboflavin * end stage keratoconus

Keywords: keratoconus cross linking riboflavin
cognitive training in heart failure study (cogtrain-hf)

Conditions: Congestive Heart Failure; Cognitive Impairment

Summary: the daily routine in clinical settings often showed cognitive impairments in patients with congestive heart failure, particularly in terms of executive functions, episodic memory, perceptual speed and attention. it is assumed that cognitive impairments in patients with congestive heart failure may lead to deficits in medication-adherence and self-care abilities, resulting in increased healthcare costs. recent studies reported performance improvements after cognitive training that transferred to new, untrained tasks and abilities in healthy subjects across a wide range of ages. this study investigates the effects of cognitive training in patients with congestive heart failure.

cognitive functions of patients with congestive heart failure (nyha ii-iii) before (pretest) and after (posttest) cognitive-training intervention are investigated. changes in cognitive functions are compared to changes in two control groups: 1) age and gender matched active control group 2) age and gender matched passive waiting list control group. the neuropsychological test battery applied at pretest and posttest includes measures of episodic memory, working memory, short-term memory, executive functions, perceptual speed and intelligence. in addition, the investigators apply standardized questionnaires of self-assessed quality of life, cognitive functioning in daily life, selfcare, and psychological well-being (depression, anxiety and personality). relevant physiological data such as ejection fraction, heartrate, n-terminal pro brain natriuretic peptide (nt-pro-bnp) as well as drug blood level are recorded.

Eligibility criteria:
inclusion criteria: * congestive heart failure * nyha ii-iii exclusion criteria: * psychosis * dementia * major depression * reanimation (\<3month) * patients with assist device system

Keywords: cognitive training cognitive impairment heart failure cognition